Lewis B. Gainor filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of common shares of Clearmind Medicine Inc. as of the triggering event date of October 20, 2026.

Key Highlights

  • Reporting person: Lewis B. Gainor, an individual U.S. citizen residing at PO Box 20301, Waco, TX 76702.
  • Shares beneficially owned: 25,300 common shares, no par value, of Clearmind Medicine Inc.
  • Percent of class: 4.9% of the outstanding class of common shares.
  • Sole voting and dispositive power: 25,300 shares, with no shared voting or dispositive power reported.
  • Triggering event date: October 20, 2026, per the filing.
  • Certification: The filer certified that the shares "were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

Gainor's Schedule 13G Filing for Clearmind Medicine Common Shares

According to the Schedule 13G filed with the Securities and Exchange Commission, Lewis B. Gainor reported beneficial ownership of 25,300 common shares, no par value, of Clearmind Medicine Inc. (CUSIP 185053709). The filing identifies the issuer's principal executive offices as 101-1220 West 6th Avenue, Vancouver, British Columbia, V6H1A5. The filer is described as an individual ("IN" type of reporting person) and a citizen of the United States of America.

The filing discloses that Gainor holds sole voting power and sole dispositive power over all 25,300 shares, with zero shares subject to shared voting or shared dispositive power. The aggregate amount beneficially owned is stated as 25,300 shares, representing 4.9% of the class. Item 5 of the filing indicates this constitutes ownership of 5 percent or less of the class. Items 6, 7, 8, and 9 are each stated as "Not Applicable," indicating no ownership on behalf of another person, no subsidiary involvement, and no group membership or dissolution.

In the certification under Item 10, the filer stated that the securities reported were not acquired and are not held for the purpose of changing or influencing control of Clearmind Medicine Inc., and were not acquired in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11. The statement was signed by Lewis B. Gainor on October 27, 2026.

What Was Disclosed

Lewis B. Gainor disclosed beneficial ownership of 25,300 common shares of Clearmind Medicine Inc., equal to 4.9% of the class, with sole voting and dispositive power, via a Schedule 13G filed October 27, 2026, covering an event dated October 20, 2026.